Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$2.72
-6.8%
$5.28
$2.60
$44.80
$1.85M0.361.15 million shs265,764 shs
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
$5.51
$4.00
$6.92
$200.47M2.16189,500 shs64,100 shs
MYOS
MYOS RENS Technology
$3.35
$0.74
$3.85
$16.70M1.081.68 million shsN/A
ULURU Inc. stock logo
ULUR
ULURU
$0.00
$0.10
$0.79
$5.35M-3.136,691 shsN/A
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-31.93%-1.02%-32.95%-64.48%-89.57%
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
0.00%0.00%0.00%0.00%0.00%
MYOS
MYOS RENS Technology
0.00%0.00%0.00%-54.41%+389.29%
ULURU Inc. stock logo
ULUR
ULURU
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
1.3593 of 5 stars
3.52.00.00.02.30.00.6
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
MYOS
MYOS RENS Technology
N/AN/AN/AN/AN/AN/AN/AN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
3.00
Buy$40.001,370.59% Upside
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/A
MYOS
MYOS RENS Technology
N/AN/AN/AN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/A

Current Analyst Ratings

Latest BPTH, MYOS, KMPH, and ULUR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00
3/27/2024
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $40.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
$10.72M0.00N/A23.28$3.63 per share0.00
MYOS
MYOS RENS Technology
$1.03M0.00N/AN/A$0.13 per share0.00
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08M-$40.80N/AN/AN/AN/A-375.74%-248.63%5/10/2024 (Estimated)
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/A
MYOS
MYOS RENS Technology
-$4.26MN/AN/AN/AN/A-277.82%-166.68%-104.95%N/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest BPTH, MYOS, KMPH, and ULUR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/8/202412/31/2023
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$5.40-$5.40N/AN/AN/AN/A    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/AN/A
MYOS
MYOS RENS Technology
N/AN/AN/AN/AN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
1.60
1.60
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
0.14
10.10
10.10
MYOS
MYOS RENS Technology
0.11
3.78
1.94
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
19.39%
MYOS
MYOS RENS Technology
4.97%
ULURU Inc. stock logo
ULUR
ULURU
N/A

Insider Ownership

CompanyInsider Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
3.05%
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
1.10%
MYOS
MYOS RENS Technology
45.30%
ULURU Inc. stock logo
ULUR
ULURU
1.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
10680,000658,000Optionable
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
2234.51 million34.13 millionOptionable
MYOS
MYOS RENS Technology
1512.19 millionN/ANot Optionable
ULURU Inc. stock logo
ULUR
ULURU
230.57 million30.24 millionNot Optionable

BPTH, MYOS, KMPH, and ULUR Headlines

SourceHeadline
Five great walks in the Northern TerritoryFive great walks in the Northern Territory
australiangeographic.com.au - April 23 at 9:22 AM
What a modern retirement plan should look likeWhat a modern retirement plan should look like
smh.com.au - April 21 at 7:56 AM
Aussies ‘locked out’ of national parks to protect cultural heritageAussies ‘locked out’ of national parks to protect cultural heritage
news.com.au - April 21 at 7:56 AM
The rise of booze-free backpacking: why gen Z are choosing to travel soberThe rise of booze-free backpacking: why gen Z are choosing to travel sober
theguardian.com - April 21 at 7:56 AM
Bolt: Ban on non-Aborigines is the new apartheidBolt: Ban on non-Aborigines is the new apartheid
heraldsun.com.au - April 21 at 7:56 AM
Colin and Joh explore UluruColin and Joh explore Uluru
bhg.com.au - April 19 at 7:00 PM
The 11 Best Road Trips in the WorldThe 11 Best Road Trips in the World
outsideonline.com - April 18 at 4:50 AM
Truth-telling risks inflaming community conflict: reportTruth-telling risks inflaming community conflict: report
afr.com - April 18 at 4:50 AM
It’s political spending that feeds inflation, not Coles and WooliesIt’s political spending that feeds inflation, not Coles and Woolies
afr.com - April 18 at 4:50 AM
Truth, colonisation and Yoorrook: what is Victoria’s truth-telling inquiry and what will it achieve?Truth, colonisation and Yoorrook: what is Victoria’s truth-telling inquiry and what will it achieve?
theguardian.com - April 18 at 4:50 AM
Better Homes & Gardens: April 19Better Homes & Gardens: April 19
tvtonight.com.au - April 17 at 5:32 PM
LET THE GAMES BEGIN! REVERSE: 1999 FIRES OFF AUSTRALIA-THEMED VERSION 1.5 PHASE ONE UPDATE “REVIVAL! THE ULURU GAMES” TODAYLET THE GAMES BEGIN! REVERSE: 1999 FIRES OFF AUSTRALIA-THEMED VERSION 1.5 PHASE ONE UPDATE “REVIVAL! THE ULURU GAMES” TODAY
capsulecomputers.com.au - April 16 at 9:30 PM
Miguel Maestre teams up with Tourism NT and Luxury EscapesMiguel Maestre teams up with Tourism NT and Luxury Escapes
ntnews.com.au - April 15 at 8:22 PM
‘My kids were heartbroken over Bluey’s biggest episode’‘My kids were heartbroken over Bluey’s biggest episode’
adelaidenow.com.au - April 14 at 2:03 PM
The cost of marrying a British princeThe cost of marrying a British prince
msn.com - April 14 at 2:03 PM
Former soldier returns boomerang from nuclear test era to Maralingas traditional ownersFormer soldier returns boomerang from nuclear test era to Maralinga's traditional owners
msn.com - April 14 at 2:03 PM
It’s time to tick Uluru off your family adventure bucket listIt’s time to tick Uluru off your family adventure bucket list
ntnews.com.au - April 12 at 8:48 PM
The Inland Sea: An Australian OdysseyThe Inland Sea: An Australian Odyssey
avclub.com - April 12 at 8:55 AM
There’s nothing to sea here: Cruise dining goes inland for some spectacular new experiencesThere’s nothing to sea here: Cruise dining goes inland for some spectacular new experiences
msn.com - April 12 at 12:54 AM
Host a Screening of Living Black: Never Meant To HappenHost a Screening of Living Black: Never Meant To Happen
sbs.com.au - April 10 at 7:27 AM
Qantas launches surprise 72-hour flight sale to more than 60 domestic destinationsQantas launches surprise 72-hour flight sale to more than 60 domestic destinations
7news.com.au - April 9 at 11:26 AM
How to see the next 20 years of eclipses, including the eclipse of a lifetimeHow to see the next 20 years of eclipses, including the eclipse of a lifetime
msn.com - April 9 at 11:26 AM
Ultra-rare, bizarre-looking blind mole photographed in AustraliaUltra-rare, bizarre-looking blind mole photographed in Australia
msn.com - April 9 at 11:26 AM
I Lived Out of a Backpack for 2 Years on Working Holidays, and These Are the 17 Items I Relied on — From $8I Lived Out of a Backpack for 2 Years on Working Holidays, and These Are the 17 Items I Relied on — From $8
msn.com - April 8 at 1:24 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bio-Path logo

Bio-Path

NASDAQ:BPTH
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Zevra Therapeutics logo

Zevra Therapeutics

NASDAQ:KMPH
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

MYOS RENS Technology

NASDAQ:MYOS
MedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada.
ULURU logo

ULURU

OTCMKTS:ULUR
ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas.